Role of galanin in the regulation of somatotrope and gonadotrope function in young ovulatory women.

The aim of the study was to elucidate the role of the neuropeptide galanin in the regulation of somatotropic and gonadotropic function in normal women. Thirteen normally ovulating (aged 28 to 40 years), non-obese (body mass index, 18.4 to 27.1 kg/m2) women with infertility due to a tubal or male factor were studied. Each woman underwent three tests: (1) bolus intravenous (IV) injection of growth hormone (GH)-releasing hormone (GHRH) (1-29)NH2 1 microgram/kg plus gonadotropin-releasing hormone (GnRH) 100 micrograms at time 0; (2) IV infusion of porcine galanin 500 micrograms in 100 mL saline from -10 minutes; and (3) bolus IV injection of GHRH(1-29)NH2 1 microgram/kg plus GnRH 100 micrograms at time 0 plus IV infusion of porcine galanin 500 micrograms in 100 mL saline from -10 to +30 minutes. All results are expressed as the mean +/- SEM. GH peak after GHRH was 14 +/- 5 micrograms/L; porcine galanin significantly increased serum GH (GH peak, 7.3 +/- 1.2) with respect to baseline levels. No significant differences were observed between either GH peak or GH absolute values after galanin as compared with GHRH alone. Porcine galanin significantly enhanced GH response to GHRH (peak, 31.4 +/- 4.4 micrograms/L) with respect to either GHRH or galanin alone. Luteinizing hormone (LH)/follicle-stimulating hormone (FSH) peaks after GnRH were 16.5 +/- 5.3 and 17.4 +/- 4 IU/L, respectively. Porcine galanin did not cause significant increases in serum LH and FSH levels with respect to baseline.(ABSTRACT TRUNCATED AT 250 WORDS)

[Longitudinal excursion of the sciatic nerve: an experimental study in the adult rat]. / L'excursion longitudinale du nerf sciatique: étude expérimentale chez le rat adulte.

Every nerve must have the capacity to adapt to different positions by passive movement relative to the surrounding tissue. This capacity is called longitudinal excursion (LE). The LE of the sciatic nerve has been studied in 40 Wistar rats. The LE was measured, the nerve was cut, sutured, a metallic body was put into the anastomotic site for later radiographic controls (at the 8th week) and then the anastomosis was protected with different kinds of tissue. After 16 weeks the sciatic nerve was exposed, the LE was measured again and the nerve was dissected out for light microscopy. The LE is produced by two mechanisms: 1) rectification of the undulating course of the nerve and 2) elasticity of the neural connective tissue sheaths. The paraneurim provides a gliding tissue. During flexion movements, it acts as an external support and keeps the nerve under a longitudinal compression force. The normal LE is the release of this compression. These properties enable the nerve to glide without changing its diameter. The gag after nerve section is approximately 75% of LE. After repairing the nerve the new LE is 55% of the original value. In peripheral nerve surgery, to create a new nerve-bed or to protect the anastomoses, a muscle flap should be avoided. On the other hand, no difference could be found between other tissue flaps. When transposing a nerve, the submuscular position is preferable to the intramuscular position.

The vascular rein technique: a new way for thumb reconstruction.

Many surgical procedures have already been published for reconstruction of an amputated thumb. A new technique is proposed consisting of a composite island transfer of part or of the whole distal phalanx of the middle finger. A double vascular bundle is provided and microsurgery is not necessary. 13 cases have been carried out with a maximum follow up of 6 years.

Metergoline and bromocriptine in the management of tumoral and idiopathic hyperprolactinemia.

59 patients affected by amenorrhea or anovulation, 37 of whom also with galactorrhea, and with hyperprolactinemia of unknown origin (idiopathic hyperprolactinemia, 24 patients) or due to a pituitary microadenoma (tumoral hyperprolactinemia, 35 patients) were treated with metergoline (4-12 mg/day) or with bromocriptine (2.5 to 10 mg/day) for 90 days. The effectiveness of the two treatments was assessed on clinical grounds and by evaluating at monthly intervals serum progesterone levels, during the presumed luteal phase, and serum prolactin levels. The success rate with the two drugs was superimposable in terms of disappearance of galactorrhea and return of menses, normalization of prolactin levels and induction of ovulation. Also the number of pregnancies obtained (7 with metergoline, 9 with bromocriptine) was similar. With both drugs, the majority of patients responded to the treatment within the first month.

Benserazide and nomifensine in the diagnosis of prolactin-secreting pituitary adenomas.

Benserazide, an inhibitor of dopa-decarboxylase, stimulates prolactin (Prl) release in normal women and in puerperae; nomifensine, a dopaminergic drug able to release dopamine and to inhibit its re-uptake at the post-synaptic level, inhibits Prl release in the same subjects. Similar modifications of Prl release are evident in selected cases of non-tumoral hyperprolactinaemia, while neither drug modifies Prl release in patients with a Prl-secreting pituitary adenoma, in patients with 'functional' hyperprolactinaemia and in patients with 'functional' hyperprolactinaemia and in patients with minor abnormalities of sellar tomography. Neither drug modified Prl release in patients with macro- or microadenomas; several patients in the remaining groups failed to respond to one or both tests, the concordance between the two tests averaging 75%. Patients responding to both tests, to one test or to neither test showed progressively higher basal Prl levels. Since benserazide and nomifensine can indicate the presence of a pituitary adenoma earlier than sellar tomography, our results indicate that patients with no Prl response to one or to both tests probably harbour a pituitary adenoma which cannot yet be revealed by sellar tomography.